

=> s us6071966/pn
L1 1 US6071966/PN

=> select l1
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E122 ASSIGNED

=> s e4-e120

12 219810-59-0/BI
7 219810-60-3/BI
7 219810-61-4/BI
8 219810-62-5/BI
8 219810-65-8/BI
7 219810-66-9/BI
8 219810-67-0/BI
7 219810-68-1/BI
8 219810-69-2/BI
3 219810-70-5/BI
4 219810-71-6/BI
4 219810-72-7/BI
7 219810-73-8/BI
4 219810-74-9/BI
3 219810-75-0/BI
3 219810-76-1/BI
3 219810-77-2/BI
3 219810-78-3/BI
3 219810-79-4/BI
3 219810-80-7/BI
4 219810-81-8/BI
4 219810-82-9/BI
4 219810-83-0/BI
4 219810-84-1/BI
4 219810-85-2/BI
3 219810-86-3/BI
3 219810-87-4/BI
4 219810-88-5/BI
4 219810-89-6/BI
4 219810-90-9/BI
4 219810-91-0/BI
4 219810-92-1/BI
4 219810-93-2/BI
4 219810-94-3/BI
4 219810-95-4/BI
4 219810-97-6/BI
3 219810-98-7/BI
3 219810-99-8/BI
3 219811-00-4/BI
4 219811-01-5/BI
4 219811-02-6/BI
4 219811-03-7/BI
4 219811-04-8/BI
4 219811-05-9/BI
4 219811-06-0/BI
4 219811-07-1/BI
4 219811-08-2/BI
4 219811-09-3/BI
4 219811-10-6/BI
4 219811-11-7/BI
4 219811-13-9/BI
4 219811-14-0/BI
3 219811-15-1/BI
3 219811-16-2/BI
4 219811-17-3/BI

Handwritten:
G2704
Instant
Compounds

4 219811-18-4/BI
 3 219811-19-5/BI
 3 219811-20-8/BI
 3 219811-21-9/BI
 3 219811-22-0/BI
 3 219811-23-1/BI
 3 219811-24-2/BI
 3 219811-25-3/BI
 3 219811-26-4/BI
 6 219811-29-7/BI
 3 219811-30-0/BI
 2 219811-31-1/BI
 7 219835-34-4/BI
 5 219835-35-5/BI
 6 219835-36-6/BI
 5 219835-37-7/BI
 6 219835-38-8/BI
 5 219835-39-9/BI
 8 219835-40-2/BI
 5 219835-41-3/BI
 5 219835-42-4/BI
 6 219835-43-5/BI
 7 219835-44-6/BI
 5 219835-45-7/BI
 8 219835-46-8/BI
 5 219835-47-9/BI
 6 219835-48-0/BI
 5 219835-49-1/BI
 10 219835-50-4/BI
 7 219835-51-5/BI
 5 219835-52-6/BI
 5 219835-53-7/BI
 6 219835-54-8/BI
 8 219835-55-9/BI
 7 219835-56-0/BI
 5 219835-57-1/BI
 5 219835-58-2/BI
 6 219835-59-3/BI
 6 219835-60-6/BI
 4 219835-61-7/BI
 7 219835-62-8/BI
 5 219835-63-9/BI
 5 219835-64-0/BI
 5 219835-65-1/BI
 4 219835-66-2/BI
 4 219835-67-3/BI
 2 259734-04-8/BI
 2 259734-05-9/BI
 5 259734-06-0/BI
 3 259734-09-3/BI
 2 259734-10-6/BI
 2 259734-11-7/BI
 6 259734-12-8/BI
 5 259734-13-9/BI
 5 259734-14-0/BI
 5 259734-15-1/BI
 5 259734-16-2/BI
 7 259734-17-3/BI
 3 259734-18-4/BI
 5 259734-19-5/BI
 3 259747-70-1/BI
 5 259747-71-2/BI
 21 (219810-59-0/BI OR 219810-60-3/BI OR 219810-61-4/BI OR 219810-62-5/BI OR 219810-65-8/BI OR 219810-66-9/BI OR 219810-67-0/BI OR

219810-68-1/BI OR 219810-69-2/BI OR 219810-70-5/BI OR 219810-71-6/BI OR 219810-72-7/BI OR 219810-73-8/BI OR 219810-74-9/BI OR 219810-75-0/BI OR 219810-76-1/BI OR 219810-77-2/BI OR 219810-78-3/BI OR 219810-79-4/BI OR 219810-80-7/BI OR 219810-81-8/BI OR 219810-82-9/BI OR 219810-83-0/BI OR 219810-84-1/BI OR 219810-85-2/BI OR 219810-86-3/BI OR 219810-87-4/BI OR 219810-88-5/BI OR 219810-89-6/BI OR 219810-90-9/BI OR 219810-91-0/BI OR 219810-92-1/BI OR 219810-93-2/BI OR 219810-94-3/BI OR 219810-95-4/BI OR 219810-97-6/BI OR 219810-98-7/BI OR 219810-99-8/BI OR 219811-00-4/BI OR 219811-01-5/BI OR 219811-02-6/BI OR 219811-03-7/BI OR 219811-04-8/BI OR 219811-05-9/BI OR 219811-06-0/BI OR 219811-07-1/BI OR 219811-08-2/BI OR 219811-09-3/BI OR 219811-10-6/BI OR 219811-11-7/BI OR 219811-13-9/BI OR 219811-14-0/BI OR 219811-15-1/BI OR 219811-16-2/BI OR 219811-17-3/BI O

=> d ibib 1-21

all below having the instant compound

L2 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:372886 CAPLUS
 DOCUMENT NUMBER: 140:368722
 TITLE: Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors for treatment of dementia
 INVENTOR(S): Moebius, Hans-Joerg
 PATENT ASSIGNEE(S): Germany
 SOURCE: U.S. Pat. Appl. Publ., 46 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087658	A1	20040506	US 2003-691895	20031023
PRIORITY APPLN. INFO.:			US 2002-420918P	P 20021024

L2 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:368913 CAPLUS
 DOCUMENT NUMBER: 140:395498
 TITLE: Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia
 INVENTOR(S): Moebius, Hans-Joerg
 PATENT ASSIGNEE(S): Merz Pharma G.m.b.H. & Co. K.-G.a.A., Germany;
 Marsden, John Christopher
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037234	A2	20040506	WO 2003-GB4549	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-420918P P 20021024

L2 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:353140 CAPLUS

DOCUMENT NUMBER: 140:380634

TITLE: Compositions of cyclooxygenase-2 selective inhibitors
and NMDA receptor antagonists for the treatment or
prevention of neuropathic pain

INVENTOR(S): Cheung, Raymond Y.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 51 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004082543	A1	20040429	US 2002-282660	20021029
WO 2004039371	A2	20040513	WO 2003-US33089	20031017
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2002-282660 A 20021029

L2 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:270008 CAPLUS

DOCUMENT NUMBER: 140:297535

TITLE: Methods of treating age-associated memory impairment,
mild cognitive impairment, and dementias with cell
cycle inhibitors

INVENTOR(S): Reisberg, Barry

PATENT ASSIGNEE(S): New York University, USA

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026246	A2	20040401	WO 2003-US29403	20030917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,			

NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2002-411282P P 20020917

L2 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:80486 CAPLUS
DOCUMENT NUMBER: 140:139523
TITLE: NMDA receptor antagonists and their use in inhibiting
abnormal hyperphosphorylation of protein Tau
INVENTOR(S): Iqbal, Khalid; Grundke-Iqbal, Inge
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009062	A2	20040129	WO 2003-US22362	20030717
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004019118	A1	20040129	US 2003-622163	20030717
PRIORITY APPLN. INFO.:			US 2002-397434P P	20020719
OTHER SOURCE(S):	MARPAT 140:139523			

L2 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:777580 CAPLUS
DOCUMENT NUMBER: 139:292154
TITLE: Preparation of azabicyclic derivatives of
aminocyclohexane as NMDA, 5HT3, and neuronal nicotinic
receptor antagonists
INVENTOR(S): Parsons, Christopher Graham Raphael; Henrich, Markus;
Danyasz, Wojciech; Kalvinsh, Ivars; Kauss, Valerjans;
Jirgensons, Aigars; Gold, Markus; Vanejevs, Maksims
PATENT ASSIGNEE(S): Merz Pharma G.m.b.H. & Co. K.-G.a.A., Germany
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080046	A1	20031002	WO 2003-GB1236	20030321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,			

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
X US 2004034055 A1 20040219 US 2003-394670 20030321
PRIORITY APPLN. INFO.: US 2002-366386P P 20020321
OTHER SOURCE(S): MARPAT 139:292154
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:376808 CAPLUS
DOCUMENT NUMBER: 138:379247
TITLE: Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and
neuronal nicotinic receptor antagonists
INVENTOR(S): Parsons, Christopher Graham Raphael; Henrich, Markus;
Dansyz, Wojciech; Kalvinsh, Ivars; Kauss, Valerjans;
Jirgensons, Aigars
PATENT ASSIGNEE(S): Merz Pharma Gmbh & Co. Kgaa, Germany; Gold, Markus
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040084	A1	20030515	WO 2002-GB5038	20021107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

X US 2003166634 A1 20030904 US 2002-288819 20021106
PRIORITY APPLN. INFO.: US 2001-350974P P 20011107
US 2001-337858P P 20011108
OTHER SOURCE(S): MARPAT 138:379247
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:249800 CAPLUS
DOCUMENT NUMBER: 139:173649
TITLE: Are neuronal nicotinic receptors a target for
antiepileptic drug development? Studies in different
seizure models in mice and rats
AUTHOR(S): Loscher, Wolfgang; Potschka, Heidrun; Wlaz, Piotr;
Danysz, Wojciech; Parsons, Christopher G.
CORPORATE SOURCE: Toxicology and Pharmacy, Department of Pharmacology,
School of Veterinary Medicine, Hannover, 30559,
Germany
SOURCE: European Journal of Pharmacology (2003), 466(1-2),
99-111
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:725218 CAPLUS
 DOCUMENT NUMBER: 138:297293
 TITLE: NMDA receptor antagonists to characterize rat renal organic cation transporter function
 AUTHOR(S): Fourie, Jeanne; Escobar, Miguel R.; Sitar, Daniel S.
 CORPORATE SOURCE: Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, R3E 0W3, Can.
 SOURCE: European Journal of Pharmacology (2002), 452(1), 1-10
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:546227 CAPLUS
 DOCUMENT NUMBER: 138:180507
 TITLE: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats
 AUTHOR(S): Rogoz, Zofia; Skuza, Grazyna; Maj, Jerzy; Danysz, Wojciech
 CORPORATE SOURCE: Institute of Pharmacology, Polish Academy of Sciences, Krakow, PL 31-343, Pol.
 SOURCE: Neuropharmacology (2002), 42(8), 1024-1030
 CODEN: NEPHBW; ISSN: 0028-3908
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:329206 CAPLUS
 DOCUMENT NUMBER: 137:241556
 TITLE: Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists
 AUTHOR(S): Danysz, W.; Parsons, C. G.; Jirgensons, A.; Kauss, V.; Tillner, J.
 CORPORATE SOURCE: Merz+Co., Frankfurt am Main, 60318, Germany
 SOURCE: Current Pharmaceutical Design (2002), 8(10), 835-843
 CODEN: CPDEFP; ISSN: 1381-6128
 PUBLISHER: Bentham Science Publishers
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:240553 CAPLUS
 DOCUMENT NUMBER: 136:268173
 TITLE: 1-Aminoalkylcyclohexanes as trypanocidal agents
 INVENTOR(S): Kelly, John M.; Kalvinsh, Ivars; Kauss, Valerjans; Jirgensons, Aigars; Gold, Markus
 PATENT ASSIGNEE(S): Merz & Co. G.m.b.H. & Co., Germany
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024186	A1	20020328	WO 2001-EP10731	20010914
W: AU, CA, CN, CZ, CZ, GE, HU, IL, JP, KR, MX, NO, PL, UA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 6602862	B1	20030805	US 2000-664629	20000919
AU 2001087740	A5	20020402	AU 2001-87740	20010914
EP 1318800	A1	20030618	EP 2001-967349	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004509144	T2	20040325	JP 2002-528257	20010914
ZA 2001007649	A	20020514	ZA 2001-7649	20010917
NO 2003001239	A	20030318	NO 2003-1239	20030318
PRIORITY APPLN. INFO.:			US 2000-664629	A 20000919
			WO 2001-EP10731	W 20010914
OTHER SOURCE(S):		MARPAT 136:268173		
REFERENCE COUNT:		9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L2 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:935560 CAPLUS

DOCUMENT NUMBER: 136:48466

TITLE: 1-Aminoalkylcyclohexanes as 5-HT₃ and neuronal nicotinic receptor antagonists, preparation, pharmaceutical compositions, and therapeutic use thereof

INVENTOR(S): Parsons, Christopher Graham Raphael; Danysz, Wojciech; Gold, Markus; Kalvinsh, Ivars; Kauss, Valerjans; Jirgensons, Aigars

PATENT ASSIGNEE(S): Merz & Co. G.m.b.H. & Co., Germany

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098253	A2	20011227	WO 2001-EP6964	20010619
W: AU, CA, CN, CZ, CZ, FI, FI, GE, HU, IL, JP, KR, MX, NO, PL, UA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
ZA 2001004187	A	20021122	ZA 2001-4187	20010522
EP 1303477	A2	20030423	EP 2001-960342	20010619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004501130	T2	20040115	JP 2002-504209	20010619
NO 2002006103	A	20030219	NO 2002-6103	20021219
PRIORITY APPLN. INFO.:			US 2000-597102	A 20000620
			WO 2001-EP6964	W 20010619
OTHER SOURCE(S):		MARPAT 136:48466		

L2 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:429280 CAPLUS

DOCUMENT NUMBER: 135:251854

TITLE: The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT₃ receptor currents in

cultured HEK-293 and N1E-115 cell systems in a non-competitive manner
 AUTHOR(S): Rammes, G.; Rupprecht, R.; Ferrari, U.; Zieglgansberger, W.; Parsons, C. G.
 CORPORATE SOURCE: Max-Planck-Institute of Psychiatry, Munchen, D-80804, Germany
 SOURCE: Neuroscience Letters (2001), 306(1-2), 81-84
 CODEN: NELED5; ISSN: 0304-3940
 PUBLISHER: Elsevier Science Ireland Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:338511 CAPLUS
 DOCUMENT NUMBER: 134:340433
 TITLE: Preparation of N-(alkylcyclohexyl)azacycloalkanes as anticonvulsants
 INVENTOR(S): Gold, Markus; Danysz, Wojciech; Parsons, Christopher
 Graham Raphael; Kalvinsh, Ivars; Kauss, Valerjans; Jirgensons, Aigars
 PATENT ASSIGNEE(S): Merz & Co. Gmbh & Co., Germany
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032640	A1	20010510	WO 1999-EP8317	19991101
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1228052	A1	20020807	EP 1999-974146	19991101
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003513083	T2	20030408	JP 2001-534791	19991101
NO 2002002044	A	20020430	NO 2002-2044	20020430
PRIORITY APPLN. INFO.:			WO 1999-EP8317	W 19991101
OTHER SOURCE(S):	MARPAT 134:340433			
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L2 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:319290 CAPLUS
 DOCUMENT NUMBER: 135:101928
 TITLE: In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei
 AUTHOR(S): Kelly, John M.; Quack, Guenter; Miles, Michael M.
 CORPORATE SOURCE: Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
 SOURCE: Antimicrobial Agents and Chemotherapy (2001), 45(5), 1360-1366

CODEN: AMACCQ; ISSN: 0066-4804
 PUBLISHER: American Society for Microbiology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:535984 CAPLUS
 DOCUMENT NUMBER: 133:281550
 TITLE: Synthesis and structure-affinity relationships of
 1,3,5-alkylsubstituted cyclohexylamines binding at
 NMDA receptor PCP site
 AUTHOR(S): Jirgensons, Aigars; Kauss, Valerjans; Kalvinsh, Ivars;
 Gold, Markus R.; Danysz, Wojciech; Parsons, Chris G.;
 Quack, Gunter
 CORPORATE SOURCE: Latvian institute of Organic Synthesis, Riga, LV-1006,
 Latvia
 SOURCE: European Journal of Medicinal Chemistry (2000), 35(6),
 555-565
 CODEN: EJMCA5; ISSN: 0223-5234
 PUBLISHER: Editions Scientifiques et Medicales Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:281550
 REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:381463 CAPLUS
 DOCUMENT NUMBER: 133:17228
 TITLE: Preparation of polyalkylcyclohexane(alkan)amines as
 NMDA receptor antagonists
 INVENTOR(S): Gold, Markus; Danysz, Wojciech; Parsons, Christopher
 Graham Raphael; Kalvinsh, Ivars; Kauss, Valerjans;
 Jirgensons, Aigars
 PATENT ASSIGNEE(S): Merz & Co. Gmbh & Co., Germany
 SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 48,575,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6071966	A	20000606	US 1998-141380	19980827
PRIORITY APPLN. INFO.:			US 1997-885944	B3 19970630
			US 1998-48575	B2 19980326

OTHER SOURCE(S): MARPAT 133:17228
 REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:157723 CAPLUS
 DOCUMENT NUMBER: 132:194135
 TITLE: Preparation of cyclohexane(alkan)amines as drugs
 INVENTOR(S): Gold, Markus; Danysz, Wojciech; Parsons, Christopher
 Graham Raphael; Kalvinsh, Ivars; Kauss, Valerjans;
 Jirgensons, Aigars
 PATENT ASSIGNEE(S): Merz & Co. G.m.b.H. & Co., Germany
 SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 885,944,
 abandoned.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6034134	A	20000307	US 1998-141381	19980827
PT 1009732	T	20031031	PT 1998-939579	19980624
CN 1136186	B	20040128	CN 1998-806775	19980624
ES 2200358	T3	20040301	ES 1998-939579	19980624
CZ 293248	B6	20040317	CZ 1999-4571	19980624
ZA 9805678	A	20000110	ZA 1998-5678	19980629
ZA 2002002908	A	20030714	ZA 2002-2908	20020412

PRIORITY APPLN. INFO.: US 1997-885944 B2 19970630
OTHER SOURCE(S): MARPAT 132:194135
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:159243 CAPLUS
DOCUMENT NUMBER: 130:347295
TITLE: Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization
AUTHOR(S): Parsons, Chris G.; Danysz, Wojciech; Bartmann, Annette; Spielmanns, Peter; Frankiewicz, Tadeusz; Hesselink, Mayke; Eilbacher, Bernd; Quack, Gunter
CORPORATE SOURCE: Department of Pharmacology, Merz + Co., Frankfurt am Main, D-60318, Germany
SOURCE: Neuropharmacology (1999), 38(1), 85-108
CODEN: NEPHBW; ISSN: 0028-3908
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:48692 CAPLUS
DOCUMENT NUMBER: 130:119606
TITLE: 1-amino-alkylcyclohexane NMDA receptor antagonists, preparation, and therapeutic use
INVENTOR(S): Gold, Markus; Danysz, Wojciech; Parsons, Christopher
Graham Raphael; Kalvinsh, Ivars; Kauss, Valerjans; Jirgensons, Aigars
PATENT ASSIGNEE(S): Merz & Co. G.m.b.H. & Co., Germany
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901416	A2	19990114	WO 1998-EP4026	19980624
WO 9901416	A3	19990819		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9888042	A1	19990125	AU 1998-88042	19980624
AU 724974	B2	20001005		
EP 1009732	A2	20000621	EP 1998-939579	19980624
EP 1009732	B1	20030521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV				
JP 2002511873	T2	20020416	JP 1999-506323	19980624
AT 240936	E	20030615	AT 1998-939579	19980624
PT 1009732	T	20031031	PT 1998-939579	19980624
CN 1136186	B	20040128	CN 1998-806775	19980624
ES 2200358	T3	20040301	ES 1998-939579	19980624
CZ 293248	B6	20040317	CZ 1999-4571	19980624
ZA 9805678	A	20000110	ZA 1998-5678	19980629
MX 9911993	A	20000930	MX 1999-11993	19991217
FI 9902801	A	19991229	FI 1999-2801	19991229
NO 9906548	A	20000228	NO 1999-6548	19991229
ZA 2002002908	A	20030714	ZA 2002-2908	20020412
PRIORITY APPLN. INFO.:			US 1997-885944	A 19970630
			WO 1998-EP4026	W 19980624
OTHER SOURCE(S):			MARPAT 130:119606	

=> d his

(FILE 'HOME' ENTERED AT 14:59:06 ON 25 JUN 2004)

FILE 'CAPLUS' ENTERED AT 14:59:23 ON 25 JUN 2004

L1 1 S US6071966/PN

SELECT L1 1 RN

L2 21 S E4-E120

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:46:46 ON 25 JUN 2004

L3 189 S EMESIS(S) (CNS OR CENTRAL(3A)NERVOUS(4A)SYSTEM)

FILE 'MEDLINE' ENTERED AT 15:57:42 ON 25 JUN 2004

L4 14 S L3 NOT PY>=1999

L5 710 S (EMESIS OR VOMIT?) (L) (CNS OR CENTRAL(3A)NERVOUS(4A)SYSTEM)

L6 531 S L5 NOT PY>=1999

L7 6 S (APPETITE(4A)DISORDER#) (L) (CNS OR CENTRAL(3A)NERVOUS(4A)SYSTE

L8 12 S (CEREBELLAR(3A)TREMOR) (L) (CNS OR CENTRAL(3A)NERVOUS(4A)SYSTEM

=>

99597,102 ✓

ACCESSION NUMBER: 97081306 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9118822
TITLE: Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
AUTHOR: Wilde M I; Markham A
CORPORATE SOURCE: Adis International Limited, Auckland, New Zealand.
SOURCE: Drugs, (1996 Nov) 52 (5) 773-94. Ref: 185
Journal code: 7600076. ISSN: 0012-6667.
PUB. COUNTRY: New Zealand
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199704
ENTRY DATE: Entered STN: 19970506
Last Updated on STN: 19970506
Entered Medline: 19970422

AB The use of ondansetron, a selective serotonin 5-HT₃ receptor antagonist, is well established in patients with nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia and surgery. The wide distribution of 5-HT₃ receptors in the body and the role of these receptors in disease have provided the rationale for investigation of ondansetron in novel applications. Preliminary data have shown ondansetron to have clinical benefit in patients with nausea and vomiting associated with drug overdosage or poisoning, anti-infective or antidepressant therapies, uraemia or neurological trauma, and in patients with pruritus. Patients with gastrointestinal motility disorders (e.g. carcinoid syndrome, irritable bowel syndrome, diarrhoea associated with cryptosporidiosis or diabetes, and chronic refractory diarrhoea) have also shown some improvement when treated with ondansetron, as have patients with certain pain or CNS-related disorders [e.g. alcohol (ethanol) dependence, opiate withdrawal, vertigo, cerebellar tremor and Parkinson's disease treatment-related psychosis]. In contrast to conventional antiemetics, ondansetron is generally well tolerated with a lower incidence of sedation and only isolated case reports of extrapyramidal reactions. Furthermore, unlike dopamine receptor-blocking neuroleptics, ondansetron does not appear to worsen the symptoms of Parkinson's disease. Thus, in addition to its established indications, preliminary results suggest that ondansetron may be beneficial in a number of novel applications. This drug may represent a treatment alternative in patients with refractory disease, or an effective treatment of conditions for which current therapies are either poorly tolerated or not available. Further investigation of ondansetron in a range of potential new applications appears to be warranted.

87/597, 102

ACCESSION NUMBER: 1998105332 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9443121
TITLE: Vomiting and gastroesophageal motor activity in
children with disorders of the central
nervous system.
COMMENT: Comment in: J Pediatr Gastroenterol Nutr. 1998
Sep;27(3):373-4. PubMed ID: 9740220
AUTHOR: Ravelli A M; Milla P J
CORPORATE SOURCE: Department of Gastroenterology, Institute of Child Health,
London, United Kingdom.
SOURCE: Journal of pediatric gastroenterology and nutrition, (1998
Jan) 26 (1) 56-63.
Journal code: 8211545. ISSN: 0277-2116.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199802
ENTRY DATE: Entered STN: 19980226
Last Updated on STN: 20000303
Entered Medline: 19980213

AB BACKGROUND: Vomiting is common in children with disorders of the
central nervous system (CNS) and is
usually ascribed to gastroesophageal reflux (GER). However, recent
acquisitions on the pathophysiology of vomiting suggest that the
dysmotility of the foregut may be more widespread. METHODS: Fifty-five
children with CNS disorders, 50 of whom suffered from retching
and/or vomiting (18 following fundoplication) were studied. We
assessed GER by 24 hour pH monitoring and endoscopy, gastric electrical
activity by electrogastrography, and gastric half-emptying time (T1/2) of
a milk meal by electrical impedance tomography. RESULTS: Of the 50
vomiting patients, 29 had GER (reflux index of 5.7%-87.4%;
controls: < 5%), and 31 had gastric dysrhythmias (12 tachyarrhythmia at
5.5-11.2 cpm, 4 bradyarrhythmia at 1.7-1.9 cpm, 15 unstable electrical
activity; controls; 2.2-4.0 cpm). Sixteen patients had GER and gastric
dysrhythmias. Eleven of 18 patients with fundoplication had gastric
dysrhythmias. Gastric T1/2 was delayed in 12 of 13 patients with gastric
dysrhythmia (6 with GER), versus 2 of 5 with GER alone. No abnormalities
were detected in the 5 patients who did not suffer from vomiting.
CONCLUSIONS: Children with CNS disorders who vomit
have abnormal gastric motility as often as GER. Following fundoplication,
many patients continue to have symptoms possibly related to gastric
dysrhythmias, the effects of which may be unmasked by fundoplication.
Foregut dysmotility may be related to abnormal modulation of the enteric
nervous system by the CNS or to involvement of the enteric
nervous system by the same process affecting the brain.

09/597, 62

ACCESSION NUMBER: 85102106 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2857138
TITLE: Mechanisms of appetite modulation by drugs.
AUTHOR: Sullivan A C; Gruen R K
SOURCE: Federation proceedings, (1985 Jan) 44 (1 Pt 1) 139-44.
Ref: 51
Journal code: 0372771. ISSN: 0014-9446.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198502
ENTRY DATE: Entered STN: 19900320
Last Updated on STN: 19970203
Entered Medline: 19850225

AB The regulation of appetite is a complex process that we are just beginning to understand. It consists of both central and peripheral elements and involves the integration by the brain of a variety of signals from peripheral organs transmitted by neurotransmitters, peptides, hormones, and metabolites. All available anorectic drugs act by central mechanisms and have several disadvantages including limited effectiveness, side effects on the **central nervous system**, the development of tolerance, abuse potential, and rebound hyperphagia on discontinuance. Several appetite-modulating agents have been tested in animals that act by peripheral mechanisms and do not produce tolerance or rebound hyperphagia, which suggests that peripherally acting anorectic drugs may provide novel therapeutic approaches to **disorders of appetite** regulation in humans.